American Society of Hematology

ASH Meeting on Hematologic Malignancies Provides Important Clinical Updates

Newest ASH Meeting Will Help Clinicians Translate the Latest Research into New Patient Care Strategies

Published on: September 15, 2015

(WASHINGTON, September 15, 2015) – The American Society of Hematology (ASH), the world’s largest professional organization dedicated to the causes and treatments of blood disorders, will bring together practitioners from around the world for the ASH Meeting on Hematologic Malignancies, September 17-19 in Chicago. The meeting will feature the top experts in the field, who will share their strategies for caring for patients with hematologic malignancies. 

Treatment options for cancers of the blood, including leukemia, lymphoma, and myeloma, are progressing at a rapid pace with advancements in precision medicine and the development of novel agents. To best convey the optimal use of these new agents and techniques in patient care, the ASH Meeting on Hematologic Malignancies will follow a case-based discussion format focusing on real-life examples from top international experts. Modeled after a popular series in ASH’s journal Blood, these 24 “How I Treat” sessions will showcase the speakers’ evidence-based treatment approaches, including discussions on standard of care, specialized disease complications, and best practices for integrating new drugs into practice. Attendees are encouraged to bring questions about their own challenging clinical cases to be discussed during interactive panel discussions throughout the two-day program. 

In addition to “How I Treat” presentations, the meeting will preview the latest clinical research to be released before the 57th ASH Annual Meeting and Exposition in Orlando. Oral abstract presentations will highlight the latest advances in hematologic malignancies, including management of HIV-associated Hodgkin lymphoma, a new study making the case for immunotherapy after stem cell transplant in myeloma patients, and the risk factors for a debilitating complication of chemotherapy associated with loss of bone tissue in children with acute leukemia. Additional research will be featured through poster session presentations.

“The ASH Meeting on Hematologic Malignancies is special in that it offers community-based physicians, as well as academic clinicians, fellows, and other members of the hematology caregiver team, an opportunity to interact directly with world-renowned experts and have their questions answered in real time,” said ASH President David A. Williams, MD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School. “As a number of new agents to treat hematologic malignancies have recently become available, attendees will benefit from this in-depth exploration of their use based on experiences from real-life practice.”

For the complete ASH Meeting on Hematologic Malignancies program and “How I Treat” session preview videos, visit the ASH website at http://www.hematology.org/Malignancies. Up-to-the-minute meeting information can also be found on Twitter by following @ASH_Hematology and #ASHMHM15.


The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.

back to top